Health Canada has approved Abbott’s sensor-based glucose monitoring technology, FreeStyle Libre 2, for adults and children aged four and above with diabetes.
The system continuously measures glucose levels every minute with customisable, optional real-time alarms to alert users of critical events like hypoglycemia (low glucose levels) and hyperglycemia (high glucose levels).
Eliminating the need for painful fingersticks, the wearable technology delivers accurate and actionable information to people with diabetes and enables better management of their condition.
Abbott Canada diabetes care business general manager Marie-Flore Nabor said: “For the millions of Canadians with diabetes, Abbott’s next-generation FreeStyle Libre 2 system expands on the life-changing capabilities of our original FreeStyle Libre system with enhanced accuracy, optional alarms and now available for children.
“This latest technology will transform the way diabetes is currently managed. The FreeStyle Libre 2 is designed to simplify this often complicated-to-manage condition and is accessible and affordable to people with diabetes in Canada.”
With the help of Bluetooth technology, the system alerts users on high or low glucose levels without scanning the sensor, Abbott noted.
Worn on the back of the upper arm for up to 14 days, the FreeStyle Libre 2 sensor measures glucose levels.
Users can check their glucose reading, trend arrow, and eight-hour history with a one-second scan using FreeStyle LibreLink app or handheld reader.
The reading can be shared with physicians through the LibreLinkUp mobile app.
The system uses the same wired enzyme technology and price range of the FreeStyle Libre system, which was the first to remove painful fingersticks.
Abbott’s FreeStyle Libre 2 system will be made available to over 3.7 million Canadians with diabetes soon.